ARCHIVES

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

George Sledge Jr. Named Oncology Chief at Stanford University

October 12, 2012

ACD Asks Senate To Raise Budget Of CDC Cancer Programs

July 30, 1993

Georgetown-Hackensack Consortium Plan Points to Rising Value of NCI Designation

April 19, 2013

In Brief: FDA Opens Advisory Committee Consideration Of NDAs, Finds Discussion Is Not Inhibited

September 10, 1976

NCI-Approved Clinical Trials

April 29, 2005

Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million

December 5, 2014